In addition, a study of 530 pretreated advanced nonsquamous cell NSCLC patients treated with nivolumab reported that only the 3‐month PFS rate was significantly higher in the KRAS MT group than in the KRAS WT group, while the OS (4 months vs. 3 months, p = 0.5) and PFS were not significantly different (11.2 months vs. 10 months, p = 0.8).20 Here, KRAS is linked to non-small cell lung carcinoma.